BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Dec 12, 1995.
Moreover, the limited toxicity observed in this trial, particularly the absence of cardiotoxicity, suggests that DaunoXome may be useful in ameliorating the side-effects that now accompany high-dose anthracycline-based chemotherapy for metastatic breast cancer. The data, generated in a phase II study funded by NeXstar (NASDAQ:NXTR), were presented by P.S. Hupperets, M.D., of the Akademisch Ziekenhuis, in Maastricht, The Netherlands.
Eleven women with previously untreated, newly diagnosed metastatic breast cancer received DaunoXome at a dose of 100 mg/m2 every three weeks for as long as 24 weeks. Even at this moderate dose, three patients (27 percent) developed a partial response, seven (63 percent) had stable disease, and one patient (10 percent) experienced no therapeutic benefit.
Toxicity was minimal: no patients lost hair, and only two patients reported mild nausea. Six patients showed evidence of bone marrow suppresion, which did not limit treatment and which recovered without supporting therapy. No patients demonstrated signs of cardiotoxicity.
"These data demonstrate that moderate-dose DaunoXome therapy produces the same kind of response rates as conventional single-agent doxorubicin therapy, but with a much improved side-effects profile," said Michael E. Ross, NeXstar's vice president for medical and regulatory affairs.
"We believe that these results bode well not only for the expanded trials we're conducting in breast cancer, but for the other solid tumor indications in which DaunoXome is being tested. We also believe that the absence of cardiotoxicity suggests that DaunoXome may play an important role in replacing conventional anthracyclines in high-dose, multiple-agent chemotherapy regimens." Such studies are currently in progress.
DaunoXome has already been approved in the U.K. and Sweden as a primary therapy for the treatment of advanced Kaposi's sarcoma in HIV-positive patients, and is awaiting final approval in the United States for the same indication.
In addition to the phase II study in breast cancer, the Company is conducting phase II trials with DaunoXome in small-cell lung cancer, non-small cell lung cancer, hepatocellular cancer, adult and childhood leukemia, brain tumor, bladder cancer and lymphoma.
NeXstar Pharmaceuticals, Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases. The Company currently markets two drugs, AmBisome and DaunoXome. The Company has headquarters in Boulder; research, development and manufacturing facilities in San Dimas, Calif.; Antwerp, Belgium; Lakewood, Colo., and Boulder; and marketing subsidiaries worldwide.
CONTACT: NeXstar Pharmaceuticals Inc., Boulder Joseph Alper, 303/546-7717
Copyright (c) 1995/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
951212
BW951202
Copyright © 1995 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .